Phase IIa trial assessing the efficacy and safety of Enpatoran in patients with dermatomyositis and polymyositis: NEPTUNIA rationale and study design

被引：0
|
作者：
Aggarwal, R. [1 ]
Roy, S. [2 ]
Thommes, G. [3 ]
Weinelt, D. [3 ]
Chitkara, D. [4 ]
Denis, D. [5 ]
机构：
[1] Univ Pittsburgh, Pittsburgh, PA USA
[2] Ares Trading SA, Affiliate Merck KGaA, Eysins, Switzerland
[3] Merck Healthcare KGaA, Darmstadt, Germany
[4] EMD Serono Res & Dev Inst Inc, Affiliate Merck KGaA, Billerica, MA USA
[5] EMD Serono Inc, Affiliate Merck KGaA, Rockland, MA USA
来源：
NEUROMUSCULAR DISORDERS | 2024年 / 43卷
关键词：
D O I：
10.1016/j.nmd.2024.07.393
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
683P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of Panax Notoginseng Saponins (Xueshuantong) in Patients With Acute Ischemic Stroke (EXPECT) Trial: Rationale and Design
    Feng, Luda
    Han, Fang
    Zhou, Li
    Wu, Shengxian
    Du, Yawei
    Zhang, Dandan
    Zhang, Chi
    Gao, Ying
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [22] Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trial
    van Veldhuisen, Dirk J.
    Rienstra, Michiel
    Mosterd, Arend
    Alings, A. Marco
    van Asselt, Antoinette D. J.
    Bouvy, Marcel L.
    Tijssen, Jan G. P.
    Schaap, Jeroen
    van der Wall, Ernst E.
    Voors, Adriaan A.
    Boorsma, Eva M.
    Lok, Dirk J. A.
    Crijns, Harry J. G. M.
    Schut, Astrid
    Vijver, Marlene A. T.
    Voordes, Geert H. D.
    de Vos, Agaath H.
    Maas-Soer, Ester L.
    Smit, Nicoline W.
    Touw, Daan J.
    Samuel, Michelle
    van Der Meer, Peter
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (10) : 2223 - 2230
  • [23] Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
    Schwartz, Gregory G.
    Olsson, Anders G.
    Ballantyne, Christie M.
    Barter, Phillip J.
    Holme, Ingar M.
    Kallend, David
    Leiter, Lawrence A.
    Leitersdorf, Eran
    McMurray, John J. V.
    Shah, Prediman K.
    Tardif, Jean-Claude
    Chaitman, Bernard R.
    Duttlinger-Maddux, Regina
    Mathieson, John
    AMERICAN HEART JOURNAL, 2009, 158 (06) : 896 - U34
  • [24] Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis
    Perez, Evans R. Fernandez
    Crooks, James L.
    Swigris, Jeffrey J.
    Solomon, Joshua J.
    Mohning, Michael P.
    Huie, Tristan J.
    Koslow, Matthew
    Lynch, David A.
    Groshong, Steve D.
    Fier, Kaitlin
    ERJ OPEN RESEARCH, 2021, 7 (02)
  • [25] A Phase I/IIa trial examining the safety and efficacy of BI-X in patients with diabetic macular ischemia and diabetic retinopathy: The HORNBILL study
    Sivaprasad, Sobha
    Quan Dong Nguyen
    Jhaveri, Chirag
    Sen, Harsha
    Brown, David M.
    Maturi, Raj K.
    Cole, Abosede
    Giani, Andrea
    Pearce, Elizabeth
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [26] STUDY DESIGN AND RATIONALE OF HELIOS-B: A PHASE 3 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF VUTRISIRAN IN PATIENTS WITH ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY
    Shilling, Rebecca
    Karsten, Verena
    Silliman, Nancy
    Chen, Jihong
    Li, Wei
    Vest, John
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 3579 - 3579
  • [27] Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis A Randomized Phase IIa Trial
    Senolt, Ladislav
    Leszczynski, Piotr
    Dokoupilova, Eva
    Goethberg, Marie
    Valencia, Xavier
    Hansen, Brian Bekker
    Canete, Juan D.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67 (06) : 1438 - 1448
  • [28] A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)
    Hidalgo, M.
    Epelbaum, R.
    Wolpin, B. M.
    Stemmer, S. M.
    Geva, R.
    Golan, T.
    Borazanci, E.
    Borad, M.
    Pedersen, K. S.
    Park, J. O.
    Ramirez, R.
    Peled, A.
    Lustig, T. M.
    Kashtan, O. Bohana
    Rosenfeld, O.
    Sorani, E.
    Schlienger, K.
    Haras, A. Vainstein
    Von Hoff, D. D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [29] DESIGN OF A GLOBAL PHASE 2/3 RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF RAVULIZUMAB IN ADULTS WITH DERMATOMYOSITIS
    Cavagna, L.
    Aggarwal, R.
    Iikuni, N.
    Rakhade, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1750 - 1751
  • [30] Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction
    Prescott, Eva
    Pernow, John
    Saraste, Antti
    Akerblom, Axel
    Angeras, Oskar
    Erlinge, David
    Grove, Erik L.
    Hedman, Marja
    Jensen, Lisette O.
    Svedlund, Sara
    Kjaer, Magnus
    Lagerstrom-Fermer, Maria
    Gan, Li-Ming
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2020, 19
12345